Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Unveils 2026 Trends Poised to Transform Customer Engagement and Digital Ecosystems27.11.2025 11:00:00 EET | Press release
Global cloud communications platform Infobip today announces its predictions for 2026, spotlighting transformative trends set to redefine how businesses engage customers and operate across sectors. Central to these shifts are the mainstream adoption of AI-powered agents, the expansion of super apps as integrated ecosystems, and the rise of privacy-first AI models enabling scalable, compliant automation. “2026 will be a breakthrough year as generative AI and omnichannel communication converge to redefine customer engagement and digital ecosystems,”said Silvio Kutić, CEO at Infobip. “Retail and eCommerce sectors are already leading the way with hyper-personalized experiences, while healthcare and finance are rapidly adopting AI-driven solutions to enhance patient care and security. Crucially, the future of customer service lies in a human-in-the-loop approach—where AI-powered automation works hand-in-hand with human expertise to deliver both efficiency and empathy. ” AI Agents will handl
Lenovo Leads the Circular IT Shift with a New Chapter to Extend Lifecycles for Aging Tech27.11.2025 10:27:00 EET | Press release
Lenovo today introduced Lenovo Certified Refurbishment Services, a new addition to its IT sustainability and lifecycle solutions portfolio, available in EMEA. The service gives organizations the ability to refurbish their existing Lenovo devices, restoring useful life and enabling redeployment to deliver cost savings, maximize IT budgets and reduce e-waste. Most businesses still follow a binary model for their device lifecycle and refresh strategies: extend the warranty or buy new. However, Lenovo’s Certified Refurbishment Services introduce a powerful third option, refurbishing existing Lenovo devices to be reused or repurposed internally, to avoid premature retirements, balance IT refresh programs and help maximize investment. With IT budgets under pressure and sustainability goals rising to the top of corporate agendas, businesses across Europe are seeking smarter ways to extend device value while reducing environmental impact. Lenovo’s new Certified Refurbishment Services fulfill t
Stefanini Group Announces Major 2026 Investment and Expansion in France During Brazil-France Forum27.11.2025 10:00:00 EET | Press release
Stefanini Group, a global tech consulting company with expertise in digital transformation and artificial intelligence solutions, today announces a significant, multi-faceted commitment to the French market. The company plans a major investment and strategic expansion throughout 2026. The announcement is timed to the participation of Marco Stefanini, Founder and Global CEO of Stefanini Group, in the technology panel at the LIDE Brazil–France Forum, scheduled in Paris for November 26–27, 2025. “France is a crucial hub for the next wave of global digital transformation. Our increased investment here reinforces our AI-First methodology for French enterprises, leveraging cutting-edge technology to accelerate their digital journey and drive a new era of efficiency and innovation,” said Marco Stefanini. The company is aiming to substantially strengthen its presence in France through a dual approach: AI-driven organic growth and targeted acquisition. The CEO's visit will culminate with a priv
Hytera Introduces Smart PoC Radios P50E and P60 at PMRExpo 202527.11.2025 10:00:00 EET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, has officially launched its latest smart Push-to-Talk over Cellular (PoC) radios – the P50E and the P60 – at PMRExpo 2025. This launch marks a significant expansion of Hytera’s PoC portfolio, delivering the company’s most robust and comprehensive range of devices to date, offering a wide spectrum of options to meet the growing demand for PoC solutions across all sectors throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126296378/en/ Hytera unveiled new PoC radios P50E & P60 at PMRExpo 2025. Stay Smart and Safe with the P50E Featuring a compact 0.96-inch screen and a keyboard-free design, the P50E embodies the design philosophy of the P5 Series – Where Reliability Meets Simplicity. With the addition of the P50E, the P5 Series – which also includes the P50 and the P50 Pro – now provides users greater flexibility to align
SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children27.11.2025 09:15:00 EET | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/ Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia". This investigator-initiated trial is part of an ongoing project investigating the efficacy of omega-3 and omega-6 LCPUFA supplementation to enhance the effects of neuropsychological treatment in children diagnosed with developmental dyslexia (DD). LCPUFAs of the omega-3 group, such as EPA and DHA, play essential roles in microglial activity, neuroinflammatory regulation, and synaptic plasticity—pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom